| Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). | |
| | |
MedLine Citation:
|
PMID: 12501018 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to evaluate [18F]fluorodeoxyglucose ( F-FDG) imaging of recurrent or inoperable lung cancer using a hybrid positron emission tomography (PET) device of the third generation. Examinations were compared with the results of conventional staging. Thirty-six patients suffering from recurrent or primarily inoperable lung cancer (29 men, seven women; age 64.8+/-12.0 years) were examined using hybrid PET (Marconi Axis gamma-PET ) 60 min after injection of 370 MBq F-FDG. The data obtained were reconstructed iteratively. All patients received a computed tomography (CT) scan using either the spiral or multislice technique. All lesions suspicious for primary or recurrent tumour were verified by biopsy; mediastinal lymph nodes were considered as malignant, when positive histology or a small axis diameter of greater than 1 cm measured with CT in addition to progression of clinical course was found. Distant metastases were diagnosed by CT and bone scintigraphy. Using hybrid PET all lesions showed a focally elevated glucose metabolism. Lymph node involvement of the ipsilateral peribronchial and hilar station (N1) was identified in 24/26 cases (92%), in 26/29 cases (90%) of ipsilateral central manifestation (N2) and in 11/13 (85%) cases of central contralateral or supraclavicular lymphatic infestation (N3). Pulmonary spread in hybrid PET was found in 4/8 cases (50%), whereas mainly lung metastases with a diameter of 1.5 cm and smaller were missed. Pleural involvement diagnosed by CT was verified in 4/5 patients. All four patients with bony metastases in conventional staging also presented with positive findings in hybrid PET (8/9 lesions). Concordance with conventional staging was found in 28/36 of patients (78%). In 4/36 patients (11%) unknown sites of tumour were detected leading to therapeutic consequences in three patients after radiological confirmation. Hybrid PET would have led to an understaging in four cases (11%), resulting theoretically in inefficient treatment in two patients. Hybrid PET for F-FDG imaging in the staging of recurrent or primarily inoperable lung cancer supplied equal (78%) or more information (11%) compared to conventional staging procedures. Using the information of hybrid PET alone, 11% of the patients would have been understaged. We conclude that hybrid PET has the potential for use as an additional staging tool in this subgroup of patients, providing supplementary information compared to conventional staging modalities. |
| | |
Authors:
|
R A Schmid; H Hautmann; B Poellinger; W Kellner; A Moisseev; K Brinkbaeumer; M Weiss; K Hahn; S Dresel |
Related Documents
:
|
19962268 - The role of fdg pet/ct in patients with locoregional breast cancer recurrence: a compar... 17706528 - Pet versus pet/ct dual-modality imaging in evaluation of lung cancer. 8131088 - Radiolabeled antibody imaging of patients with potentially resectable colorectal adenoc... 18349458 - Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging a... 15476128 - Incarceration of the retroverted uterus at term gestation. 8570058 - Localised proton magnetic resonance spectroscopy in x-linked adrenoleukodystrophy. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 24 ISSN: 0143-3636 ISO Abbreviation: Nucl Med Commun Publication Date: 2003 Jan |
Date Detail:
|
Created Date: 2002-12-25 Completed Date: 2003-07-22 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 37-45 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, University of Munich, Germany. rupert.schmid@nuk.med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
diagnosis,
radionuclide imaging,
secondary Adult Aged Aged, 80 and over Bone Neoplasms / diagnosis, radionuclide imaging, secondary Carcinoma / diagnosis, radionuclide imaging*, secondary* Carcinoma, Large Cell / diagnosis, radionuclide imaging, secondary Carcinoma, Small Cell / diagnosis, radionuclide imaging, secondary Carcinoma, Squamous Cell / diagnosis, radionuclide imaging, secondary Female Fluorodeoxyglucose F18 / diagnostic use* Humans Lung Neoplasms / diagnosis, radionuclide imaging* Lymphatic Metastasis Male Middle Aged Neoplasm Recurrence, Local / radionuclide imaging Neoplasm Staging / methods Pleural Neoplasms / diagnosis, radionuclide imaging, secondary Radiopharmaceuticals / diagnostic use Sensitivity and Specificity Tomography, Emission-Computed / instrumentation*, methods |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complemen...
Next Document: Comparison of 99mTc-MIBI uptakes on planar images with those in excised rats organs.